MedTrace Logo

Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis

NCT03450083 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2021-02-11

Study results available
· View outcomes & findings →

Summary

Benralizumab will be used in a placebo controlled randomized study to treat severe chronic rhinosinusitis with nasal polyps

Conditions

  • Chronic Rhinosinusitis (Diagnosis)
  • Nasal Polyps
  • Eosinophilia

Interventions

DRUG

Benralizumab

30mg Benralizumab will be delivered subcutaneously

DRUG

Placebo

Subcutaneous placebo injection

Sponsors & Collaborators

Principal Investigators

  • Jody Tversky, MD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2020-01-01
Completion
2020-02-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03450083 on ClinicalTrials.gov